surmount-1 tirzepatide weight loss nondiabetic Body composition changes during reduction with in the SURMOUNT‐1 study of adults with obesity or overweight - Look - 2025 - Diabetes, Obesity and Metabolism Clinical trials of subcutaneous tirzepatide
Description
J Diabetes 16(e700290407):70029 Zatterale F, Longo M, Naderi J, Raciti GA, Desiderio A, Miele C, Beguinot F (2020) Chronic adipose tissue inflammation linking obesity to insulin resistance and type 2 diabetes
It is a GLP-1 and GIP receptor agonist
This is why some researchers draw air out of the vial after each use, though this is not always practical
Dose and treatment duration are critical determinants of weight loss magnitude
Taking doses too close together can lead to excessive drug accumulation and heightened side effects including severe nausea, vomiting, and potential dehydration
